Viyash Scientific's ₹185 Crore Debt Earns ICRA AA- Stable Rating

CHEMICALS
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Viyash Scientific's ₹185 Crore Debt Earns ICRA AA- Stable Rating
Overview

Viyash Scientific Limited has received a stronger credit rating of AA- (Stable) from ICRA for its ₹185 Crore long-term working capital facilities. This upgrade from IND A/Positive indicates improved financial health and may lead to better borrowing terms.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

What Happened

Viyash Scientific Limited announced on April 22, 2026, that ICRA has assigned a credit rating of AA- (Stable) to its long-term fund-based working capital facilities totaling ₹185 Crore. This new rating is an upgrade from the company's previous long-term rating of IND A/Positive, issued by India Ratings & Research on January 31, 2025.

Why It Matters

An AA- (Stable) rating indicates a high level of security for timely repayment of financial obligations. This strong creditworthiness can help Viyash Scientific secure more favorable borrowing terms, potentially reducing interest expenses and boosting confidence among lenders and investors.

Background

Previously, India Ratings & Research had assigned Viyash Scientific Limited an IND A/Positive rating in January 2025, indicating adequate safety for its financial obligations. The upgrade to AA- (Stable) by ICRA highlights improvements in the company's financial standing and debt management capabilities. Viyash Scientific Ltd is a manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates.

Potential Benefits

  • Access to working capital potentially at lower costs for business operations.
  • Enhanced credibility with financial institutions, strengthening its negotiating position for future debt.
  • A positive signal about the company's financial stability and management to the market.
  • Potentially easier access to larger credit lines in the future.

Potential Risks

  • ICRA may review or revise the rating if new information emerges or circumstances change that affect the company's ability to meet its debt obligations.
  • Any modifications to the terms or size of the rated instrument must be promptly reported to ICRA to prevent a rating review or revision.

What to Monitor

  • The company's continued ability to meet its debt obligations.
  • Any future reviews or rating actions by ICRA.
  • The actual impact of the rating on Viyash Scientific's borrowing costs and terms.
  • Announcements regarding changes to the terms or limits of the rated working capital facilities.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.